Alnylam Pharmaceuticals Inc (ALNY)
235.09
-2.79
(-1.17%)
USD |
NASDAQ |
Jul 26, 16:00
235.09
0.00 (0.00%)
After-Hours: 20:00
Alnylam Pharmaceuticals Revenue (TTM): 2.003B for March 31, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 2.003B |
December 31, 2023 | 1.828B |
September 30, 2023 | 1.724B |
June 30, 2023 | 1.237B |
March 31, 2023 | 1.143B |
December 31, 2022 | 1.037B |
September 30, 2022 | 960.92M |
June 30, 2022 | 884.24M |
March 31, 2022 | 879.98M |
December 31, 2021 | 844.29M |
September 30, 2021 | 749.31M |
June 30, 2021 | 687.53M |
March 31, 2021 | 570.94M |
December 31, 2020 | 492.85M |
September 30, 2020 | 400.97M |
June 30, 2020 | 345.18M |
March 31, 2020 | 285.93M |
December 31, 2019 | 219.75M |
September 30, 2019 | 169.10M |
June 30, 2019 | 101.11M |
March 31, 2019 | 86.30M |
December 31, 2018 | 74.91M |
September 30, 2018 | 91.80M |
June 30, 2018 | 106.83M |
March 31, 2018 | 92.85M |
Date | Value |
---|---|
December 31, 2017 | 89.91M |
September 30, 2017 | 69.44M |
June 30, 2017 | 66.00M |
March 31, 2017 | 58.77M |
December 31, 2016 | 47.16M |
September 30, 2016 | 37.26M |
June 30, 2016 | 29.93M |
March 31, 2016 | 29.90M |
December 31, 2015 | 41.10M |
September 30, 2015 | 57.56M |
June 30, 2015 | 62.21M |
March 31, 2015 | 60.82M |
December 31, 2014 | 50.56M |
September 30, 2014 | 37.39M |
June 30, 2014 | 35.41M |
March 31, 2014 | 36.80M |
December 31, 2013 | 47.17M |
September 30, 2013 | 44.82M |
June 30, 2013 | 52.58M |
March 31, 2013 | 64.78M |
December 31, 2012 | 66.72M |
September 30, 2012 | 78.68M |
June 30, 2012 | 82.72M |
March 31, 2012 | 82.45M |
December 31, 2011 | 82.76M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
169.10M
Minimum
Sep 2019
2.003B
Maximum
Mar 2024
866.55M
Average
844.29M
Median
Dec 2021
Revenue (TTM) Benchmarks
Pfizer Inc | 55.09B |
BridgeBio Pharma Inc | 218.60M |
Biomarin Pharmaceutical Inc | 2.472B |
Eli Lilly and Co | 35.93B |
Arvinas Inc | 71.30M |